[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
[2] |
汤钊猷, 余业勤, 周信达, 等. 不能切除肝癌的缩小疗法与序贯切除[J]. 肿瘤, 1991(4):145-147, 151.
|
[3] |
元云飞, 李锦清, 张亚奇, 等, 原发性肝癌的二步切除(附13例报告)[J]. 癌症, 1997, 16(5):358-361.
|
[4] |
Zhang Y, Huang G, Wang Y, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? ten years of experience[J]. Oncologist, 2016, 21(12):1442-1449.
|
[5] |
Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma: evaluation with analysis of 72 patients[J]. World J Surg, 1995, 19(6):784-789.
|
[6] |
赵海涛, 桑新亭, 芮静安, 等. 不能手术切除的晚期肝癌降期后切除疗效分析[J]. 中国医学科学院学报, 2009, 31(4):503-505.
|
[7] |
中国抗癌协会大肠癌专业委员会, 中国结直肠癌MDT联盟. 中国结直肠癌肝转移MDT临床实践共识(2021年版)[M]. 北京: 人民卫生出版社, 2021.
|
[8] |
Finn RS, Ikeda M, Zhu AX, et al. PhaseⅠb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26):2960-2970.
|
[9] |
中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6):618-632.
|
[10] |
Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. J Hepatocell Carcinoma, 2021(8):1233-1240.
|
[11] |
Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?[J]. J Clin Oncol, 2006, 24(24):3939-3945.
|
[12] |
Gaujoux S, Goéré D, Dumont F, et al. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?[J]. Dig Surg, 2011, 28(2):114-120.
|
[13] |
Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol, 2015, 63(1):83-92.
|
[14] |
Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J]. Cancer, 2012, 118(1):147-156.
|
[15] |
Karoui M, Penna C, Amin-hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases[J]. Ann Surg, 2006, 243(1):1-7.
|
[16] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
|
[17] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20):1894-1905.
|
[18] |
Zhu XD, Huang C, Shen YH, et al. Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4):320-329.
|
[19] |
Yang X, Xu H, Zuo B, et al. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
|
[20] |
Ho WJ, Zhu Q, Durham J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity[J]. Nat Cancer, 2021, 2(9):891-903.
|
[21] |
Cleary JM, Tanabe KT, Lauwers GY, et al. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver[J]. Oncologist, 2009, 14(11):1095-1105.
|
[22] |
Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma[J]. Drugs, 2019, 79(6):665-674.
|
[23] |
Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12):3301-3309.
|
[24] |
Goto Y, Hisaka T, Sakai H, et al. Salvage surgery for initially unresectable locally advanced hepatocellular carcinoma downstaged by hepatic arterial infusion chemotherapy[J]. Anticancer Res, 2020, 40(8):4773-4777.
|
[25] |
Chen S, Peng Z, Zhang Y, et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: abandon or repeat?[J]. Radiology, 2021, 298(3):680-692.
|
[26] |
Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy[J]. Liver Cancer, 2012, 1(2):62-70.
|
[27] |
Obi S, Sato S, Kawai T. Current status of hepatic arterial infusion chemotherapy[J]. Liver Cancer, 2015, 4(3):188-199.
|
[28] |
Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2):395-396.
|
[29] |
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7):953-960.
|
[30] |
中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J].中华消化外科杂志, 2021, 20(7):754-759.
|
[31] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
|
[32] |
Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis[J]. Nat Immunol, 2015, 16(9):907-917.
|
[33] |
Li B, Qiu J, Zheng Y, et al. Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma[J]. Ann Surg Open, 2021, 2(2):e057.
|
[34] |
Mei J, Li SH, Li QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021(8):167-176.
|
[35] |
Mei J, Tang YH, Wei W, et al. Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol, 2021(11):618206.
|
[36] |
He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021(13):17588359211002720.
|
[37] |
Liu BJ, Gao S, Zhu X, et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma[J]. Immunotherapy, 2021, 13(17):1395-1405.
|